Trial Search Results
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
Stanford is currently not accepting patients for this trial.
- Procedure: high dose chemotherapy then autologous hematopoietic cell transplant
Inclusion Criteria:- received cytoreduction prior to transplant
- adequate organ function
Exclusion Criteria:- previous transplant
- smoldering MM or benign monoclonal gammopathy
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study